[OH:1][CH:2]([C:32]1[O:33][C:34]([C:37]2[CH:42]=[CH:41][CH:40]=[CH:39][CH:38]=2)=[N:35][N:36]=1)[CH:3]([NH:8][C:9]([CH:11]([NH:23][C:24]([N:26]1[CH2:31][CH2:30][O:29][CH2:28][CH2:27]1)=[O:25])[CH2:12][S:13]([CH2:16][C:17]1[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=1)(=[O:15])=[O:14])=[O:10])[CH2:4][CH2:5][CH2:6][CH3:7].CC(OI1(OC(C)=O)(OC(C)=O)OC(=O)C2C=CC=CC1=2)=O.[O-]S([O-])(=S)=O.[Na+].[Na+].C([O-])(O)=O.[Na+]>C(Cl)Cl>[C:17]1([CH2:16][S:13]([CH2:12][CH:11]([NH:23][C:24]([N:26]2[CH2:27][CH2:28][O:29][CH2:30][CH2:31]2)=[O:25])[C:9](=[O:10])[NH:8][CH:3]([C:2]([C:32]2[O:33][C:34]([C:37]3[CH:38]=[CH:39][CH:40]=[CH:41][CH:42]=3)=[N:35][N:36]=2)=[O:1])[CH2:4][CH2:5][CH2:6][CH3:7])(=[O:15])=[O:14])[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=1Morpholine-4-carboxylic acid (1-{1-[hydroxy-(5-phenyl-[1,3,4]oxadiazol-2-yl)-methyl]-pentylcarbamoyl}-2-phenylmethane-sulfonyl-ethyl)-amide (150 mg, 0.25 mmol), in MeCl2 (5 ml), was treated with Dess-Martin periodinane (183 mg, 0.43 mmol) at room temperature. After stirring for 1 hour, 5 ml of saturated Na2S2O3—NaHCO3 were added. After a further 0.5 hours, the reaction mixture was extracted with ethyl acetate, washed with brine, dried with MgSO4 and concentrated. The residue was purified with silica gel column chromatography to yield morpholine-4-carboxylic acid {2-phenylmethanesulfonyl-1-[1-(5-phenyl-[1,3,4]oxadiazole-2-carbonyl)-pentylcarbamoyl]-ethyl}-amide (84 mg); H1 NMR(DMSO-d): 8.71 (1H, d, J=6.6 Hz, NH), 8.12-8.05 (2H, m), 7.75-7.59 (3H, m), 7.38-7.36 (5H, m), 7.04 (1H, d, J=8.1 Hz, NH), 5.12-5.01 (1H, m), 4.8-4.65 (1H, m), 4.47 (2H, s), 3.58-3.46 (4H, m), 3.35-3.2 (6H, m), 2.05-1.85 (1H, m), 1.8-1.65 (1H, m), 1.5-1.2 (4H, m), 0.87 (3H, t, J=6.9 Hz, CH3); MS: 596.8 9M−1), 598.6 (M+1).
読み込み中…